Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Therapy-relevant aberrant expression of MRP3 and BCRP mRNA in TCC-/SCC-bladder cancer tissue of untreated patients.

Rady M, Mostageer M, Rohde J, Zaghloul A, Knüchel-Clarke R, Saad S, Attia D, Mahran L, Spahn-Langguth H.

Oncol Rep. 2017 Jul;38(1):551-560. doi: 10.3892/or.2017.5695. Epub 2017 Jun 2.

PMID:
28586062
2.

Circadian variations in exsorptive transport: in situ intestinal perfusion data and in vivo relevance.

Okyar A, Dressler C, Hanafy A, Baktir G, Lemmer B, Spahn-Langguth H.

Chronobiol Int. 2012 May;29(4):443-53. doi: 10.3109/07420528.2012.668996. Epub 2012 Apr 11.

PMID:
22489638
3.

Baclofen ester and carbamate prodrug candidates: a simultaneous chromatographic assay, resolution optimized with DryLab.

Hanafi R, Mosad S, Abouzid K, Niess R, Spahn-Langguth H.

J Pharm Biomed Anal. 2011 Nov 1;56(3):569-76. doi: 10.1016/j.jpba.2011.06.023. Epub 2011 Jul 1.

PMID:
21782368
4.

Expression of RFC/SLC19A1 is associated with tumor type in bladder cancer patients.

Abdel-Haleem AM, El-Zeiry MI, Mahran LG, Abou-Aisha K, Rady MH, Rohde J, Mostageer M, Spahn-Langguth H.

PLoS One. 2011;6(7):e21820. doi: 10.1371/journal.pone.0021820. Epub 2011 Jul 8.

5.

Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat.

Shirasaka Y, Kuraoka E, Spahn-Langguth H, Nakanishi T, Langguth P, Tamai I.

J Pharmacol Exp Ther. 2010 Jan;332(1):181-9. doi: 10.1124/jpet.109.159756. Epub 2009 Sep 24.

PMID:
19779132
6.

Concentration-dependent effect of naringin on intestinal absorption of beta(1)-adrenoceptor antagonist talinolol mediated by p-glycoprotein and organic anion transporting polypeptide (Oatp).

Shirasaka Y, Li Y, Shibue Y, Kuraoka E, Spahn-Langguth H, Kato Y, Langguth P, Tamai I.

Pharm Res. 2009 Mar;26(3):560-7. doi: 10.1007/s11095-008-9771-4. Epub 2008 Nov 12.

PMID:
19002566
7.

Influence of green and black tea on folic acid pharmacokinetics in healthy volunteers: potential risk of diminished folic acid bioavailability.

Alemdaroglu NC, Dietz U, Wolffram S, Spahn-Langguth H, Langguth P.

Biopharm Drug Dispos. 2008 Sep;29(6):335-48. doi: 10.1002/bdd.617.

PMID:
18551467
8.

Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug.

Hanafy A, Spahn-Langguth H, Vergnault G, Grenier P, Tubic Grozdanis M, Lenhardt T, Langguth P.

Adv Drug Deliv Rev. 2007 Jul 10;59(6):419-26. Epub 2007 May 3.

PMID:
17566595
9.

Inhibition of folic acid uptake by catechins and tea extracts in Caco-2 cells.

Alemdaroglu NC, Wolffram S, Boissel JP, Closs E, Spahn-Langguth H, Langguth P.

Planta Med. 2007 Jan;73(1):27-32. Epub 2006 Nov 21.

PMID:
17117344
10.

Bidirectional membrane transport: simulations of transport inhibition in uptake studies explain data obtained with flavonoids.

Ofer M, Langguth P, Spahn-Langguth H.

Eur J Pharm Sci. 2006 Nov;29(3-4):251-8. Epub 2006 Jul 4.

PMID:
16934962
11.

In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect.

Tubic M, Wagner D, Spahn-Langguth H, Bolger MB, Langguth P.

Pharm Res. 2006 Aug;23(8):1712-20.

PMID:
16832615
12.

Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans.

Tubic M, Wagner D, Spahn-Langguth H, Weiler C, Wanitschke R, Böcher WO, Langguth P.

Eur J Pharm Sci. 2006 Nov;29(3-4):231-9. Epub 2006 Apr 26.

PMID:
16713700
13.

In vivo non-linear intestinal permeability of celiprolol and propranolol in conscious dogs: evidence for intestinal secretion.

Lipka E, Spahn-Langguth H, Mutschler E, Amidon GL.

Eur J Pharm Sci. 1998 Jan;6(1):75-81.

PMID:
16256710
14.

Rate-limiting biotransformation of triamterene is mediated by CYP1A2.

Fuhr U, Kober S, Zaigler M, Mutschler E, Spahn-Langguth H.

Int J Clin Pharmacol Ther. 2005 Jul;43(7):327-34.

PMID:
16035375
15.

Modulation of drug transport by selected flavonoids: Involvement of P-gp and OCT?

Ofer M, Wolffram S, Koggel A, Spahn-Langguth H, Langguth P.

Eur J Pharm Sci. 2005 Jun;25(2-3):263-71. Epub 2005 Apr 18.

PMID:
15911222
16.

Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound.

Langguth P, Hanafy A, Frenzel D, Grenier P, Nhamias A, Ohlig T, Vergnault G, Spahn-Langguth H.

Drug Dev Ind Pharm. 2005 Mar;31(3):319-29.

PMID:
15830727
17.

Selective downregulation of the MDR1 gene product in Caco-2 cells by stable transfection to prove its relevance in secretory drug transport.

Hilgendorf C, Spahn-Langguth H, Rhedin M, Regårdh CG, Löwenadler B, Langguth P.

Mol Pharm. 2005 Jan-Feb;2(1):64-73.

PMID:
15804179
18.

Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates.

El Ela AA, Härtter S, Schmitt U, Hiemke C, Spahn-Langguth H, Langguth P.

J Pharm Pharmacol. 2004 Aug;56(8):967-75.

PMID:
15285840
19.
20.

Determination of triamterene and its main metabolite hydroxytriamterene sulfate in human urine by capillary electrophoresis using ultraviolet absorbance and laser-induced fluorescence detection.

Horstkötter C, Kober S, Spahn-Langguth H, Mutschler E, Blaschke G.

J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Mar 25;769(1):107-17.

PMID:
11936683
21.

Intestinal drug efflux: formulation and food effects.

Wagner D, Spahn-Langguth H, Hanafy A, Koggel A, Langguth P.

Adv Drug Deliv Rev. 2001 Oct 1;50 Suppl 1:S13-31. Review.

PMID:
11576693
22.

The influence of age on the pharmacokinetics and pharmacodynamics of bemetizide and triamterene: a single and multiple dose study.

Mühlberg W, Mutschler E, Hofner A, Spahn-Langguth H, Arnold O.

Arch Gerontol Geriatr. 2001 Jun;32(3):265-73.

PMID:
11395172
23.
24.

Pretreatment with potent P-glycoprotein ligands may increase intestinal secretion in rats.

Hanafy A, Langguth P, Spahn-Langguth H.

Eur J Pharm Sci. 2001 Feb;12(4):405-15.

PMID:
11231107
25.

Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol.

Spahn-Langguth H, Langguth P.

Eur J Pharm Sci. 2001 Feb;12(4):361-7. Review.

PMID:
11231102
26.

Dimeric 4-aryl-1,4-dihydropyridines as novel HIV-1 protease inhibitors--affinities to intestinal P-glycoprotein.

Hilgeroth A, Dressler C, Neuhoff S, Spahn-Langguth H, Langguth P.

Pharmazie. 2000 Oct;55(10):784-5. No abstract available.

PMID:
11082847
27.

Comparative pharmacodynamics and pharmacokinetics of candesartan and losartan in man.

Fuchs B, Breithaupt-Grögler K, Belz GG, Roll S, Malerczyk C, Herrmann V, Spahn-Langguth H, Mutschler E.

J Pharm Pharmacol. 2000 Sep;52(9):1075-83.

PMID:
11045887
28.

Gemfibrozil and its oxidative metabolites: quantification of aglycones, acyl glucuronides, and covalent adducts in samples from preclinical and clinical kinetic studies.

Hermening A, Gräfe AK, Baktir G, Mutschler E, Spahn-Langguth H.

J Chromatogr B Biomed Sci Appl. 2000 May 12;741(2):129-44.

PMID:
10872583
29.

Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: drugs and analogs, stereoisomers and metabolites.

Neuhoff S, Langguth P, Dressler C, Andersson TB, Regårdh CG, Spahn-Langguth H.

Int J Clin Pharmacol Ther. 2000 Apr;38(4):168-79.

PMID:
10783826
30.

Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport.

Hilgendorf C, Spahn-Langguth H, Regårdh CG, Lipka E, Amidon GL, Langguth P.

J Pharm Sci. 2000 Jan;89(1):63-75.

PMID:
10664539
31.
32.

Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay.

Döppenschmitt S, Langguth P, Regårdh CG, Andersson TB, Hilgendorf C, Spahn-Langguth H.

J Pharmacol Exp Ther. 1999 Jan;288(1):348-57.

PMID:
9862789
33.
34.

P-Glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: the influence of culturing conditions and drug exposure on P-gp expression levels.

Anderle P, Niederer E, Rubas W, Hilgendorf C, Spahn-Langguth H, Wunderli-Allenspach H, Merkle HP, Langguth P.

J Pharm Sci. 1998 Jun;87(6):757-62.

PMID:
9607955
35.
37.

P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound.

Spahn-Langguth H, Baktir G, Radschuweit A, Okyar A, Terhaag B, Ader P, Hanafy A, Langguth P.

Int J Clin Pharmacol Ther. 1998 Jan;36(1):16-24.

PMID:
9476144
38.

Elucidation of phase I and phase II metabolic pathways of rhein: species differences and their potential relevance.

Dahms M, Lotz R, Lang W, Renner U, Bayer E, Spahn-Langguth H.

Drug Metab Dispos. 1997 Apr;25(4):442-52.

PMID:
9107544
41.

4-(6-methoxy-2-naphthyl)-2-butyl chloroformate enantiomers: new reagents for the enantiospecific analysis of amino compounds in biogenic matrices.

Büschges R, Devant R, Mutschler E, Spahn-Langguth H.

J Pharm Biomed Anal. 1996 Nov;15(2):201-20.

PMID:
8933422
42.

[Plus-minus: chirality and pharmacokinetics].

Spahn-Langguth H.

Pharm Unserer Zeit. 1996 Jul;25(4):198-9. German. No abstract available.

PMID:
8927637
43.

Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo.

Wetterich U, Spahn-Langguth H, Mutschler E, Terhaag B, Rösch W, Langguth P.

Pharm Res. 1996 Apr;13(4):514-22.

PMID:
8710739
44.

Pharmacokinetics and drug input characteristics for a diclofenac-codeine phosphate combination following oral and rectal administration.

Hanses A, Spahn-Langguth H, Meiss F, Mutschler E.

Arzneimittelforschung. 1996 Jan;46(1):57-63.

PMID:
8821519
45.

Acyl glucuronides: covalent binding and its potential relevance.

Spahn-Langguth H, Dahms M, Hermening A.

Adv Exp Med Biol. 1996;387:313-28. Review. No abstract available.

PMID:
8794225
46.

Dose-effect and kinetic-dynamic relationships of the beta-adrenoceptor blocking properties of various doses of talinolol in healthy humans.

de Mey C, Schroeter V, Butzer R, Jahn P, Weisser K, Wetterich U, Terhaag B, Mutschler E, Spahn-Langguth H, Palm D, et al.

J Cardiovasc Pharmacol. 1995 Dec;26(6):879-8.

PMID:
8606523
47.

New specific and sensitive HPLC-assays for ethacrynic acid and its main metabolite--the cysteine conjugate--in biological material.

Voith B, Spahn-Langguth H, Mutschler E.

J Pharm Biomed Anal. 1995 Oct;13(11):1373-82.

PMID:
8634355
48.

Celiprolol double-peak occurrence and gastric motility: nonlinear mixed effects modeling of bioavailability data obtained in dogs.

Lipka E, Lee ID, Langguth P, Spahn-Langguth H, Mutschler E, Amidon GL.

J Pharmacokinet Biopharm. 1995 Jun;23(3):267-86.

49.

A new rapid and sensitive high-performance liquid chromatographic assay for diclofenac in human plasma.

Hanses A, Spahn-Langguth H, Mutschler E.

Arch Pharm (Weinheim). 1995 Mar;328(3):257-60.

PMID:
7763141
50.

Supplemental Content

Loading ...
Support Center